Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.

ABSTRACT:

Background

Androgen deprivation therapy (ADT) is a front-line treatment for prostate cancer. In some men, their tumors can become refractory leading to the development of castration-resistant prostate cancer (CRPC). This causes tumors to regrow and metastasize, despite ongoing treatment, and impacts negatively on patient survival. ADT is known to stimulate the accumulation of immunosuppressive cells like protumoral tumor-associated macrophages (TAMs), myeloid-derived suppressor cells and regulatory T cells in prostate tumors, as well as hypofunctional T cells. Protumoral TAMs have been shown to accumulate around tumor blood vessels during chemotherapy and radiotherapy in other forms of cancer, where they drive tumor relapse. Our aim was to see whether such perivascular (PV) TAMs al

SUBMITTER: Al-Janabi H 

PROVIDER: S-EPMC11284826 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature